Farhat Ghaznawi

机构：Novartis (United States)

发表论文 17 篇 · 总被引 1096 次 · h-index 7

代表论文

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 (2020 · Annals of Oncology · 被引 615)
Ribociclib plus Endocrine Therapy in Early Breast Cancer (2024 · New England Journal of Medicine · 被引 379)
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study (2019 · The Lancet Haematology · 被引 30)
LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) (2020 · Annals of Oncology · 被引 20)
352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC) (2020 · Annals of Oncology · 被引 12)
Abstract GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial (2024 · Cancer Research · 被引 10)